VNDA Vanda Pharmaceuticals Inc.

20.8
-0.15  -1%
Previous Close 20.95
Open 21
Price To Book 4.49
Market Cap 1083902581
Shares 52,110,701
Volume 291,075
Short Ratio 5.46
Av. Daily Volume 435,718

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due by end of 2018.
Tradipitant
Gastroparesis
PK trial initiated with full enrollment completed 4Q 2017.
HETLIOZ (tasimelteon) - pediatric formulation
Insomnia
Approved May 26, 2016.
Fanapt
Supplemental New Drug Application (sNDA) as a maintenance treatment of schizophrenia in adults.
Approved January 31, 2014.
HETLIOZ (tasimelteon)
Insomnia
Phase 2 data released March 5, 2018 - primary endpoint met.
HETLIOZ (tasimelteon)
Jet Lag Disorder
Phase 3 initiated 4Q 2016. Data due by the end of 2018.
HETLIOZ (tasimelteon)
Smith-Magenis Syndrome
Phase 2 data released September 13, 2017 - primary endpoint not met. Phase 3 trial to commence 2Q 2018.
Tradipitant
Atopic dermatitis
Phase 1 trial to commence 2H 2018.
VTR-297
Hematologic malignancies

Latest News

  1. Lilly (LLY) Issues Update on Diabetes Drug Trulicity Label
  2. Vanda Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 1, 2018
  3. J&J's (JNJ) Invokana Label Expansion Filing Hit by FDA Delay
  4. Complimentary Technical Snapshots on Trevena and Three More Biotech Stocks
  5. Detailed Research: Economic Perspectives on Comerica, Vanda Pharmaceuticals, Acadia Healthcare, The Charles Schwab, Ares Capital, and EQT — What Drives Growth in Today's Competitive Landscape
  6. TG Therapeutics and Three Additional Stocks Under Scanner in the Biotech Space
  7. Vanda Pharmaceuticals Announces Participation at June 2018 Investor Conferences
  8. Stocks Generating Improved Relative Strength: Vanda Pharmaceuticals
  9. HETLIOZ® (tasimelteon) Effective in Treating Jet Lag during Transatlantic Travel
  10. Edited Transcript of VNDA earnings conference call or presentation 2-May-18 8:30pm GMT
  11. Investor Expectations to Drive Momentum within Plains Group Holdings, EnteroMedics, Vanda Pharmaceuticals, Cinemark, EPR Properties, and The Estee Lauder Companies — Discovering Underlying Factors of Influence
  12. Vanda Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference
  13. Vanda: 1Q Earnings Snapshot
  14. Vanda Pharmaceuticals Reports First Quarter 2018 Financial Results
  15. AVEO Pharmaceuticals (AVEO) Q1 Earnings: What's in Store?
  16. Zacks.com highlights: Illumina, Alarm.com Holdings, Copart and Vanda Pharmaceuticals
  17. 4 Top Efficient Stocks to Buy for Stellar Returns
  18. Vanda Pharmaceuticals Inc. (VNDA) Sees Hammer Chart Pattern: Time to Buy?
  19. Vanda Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 2, 2018